Want to join the conversation?
$BIIB said Bioverativ will continue commercialization of ELOCTATE and ALPROLIX, indicated for treatment of hemophilia A and B under $BIIB's existing collaboration agreement with Swedish Orphan Biovitrum AB. After spin-off, Bioverativ expects to continue development of ELOCTATE and ALPROLIX. Bioverativ plans to trade under "BIVV" ticker.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.